Compare Merck & Co., Inc. (MRK) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Merck & Co., Inc. trades at $142.38 (market cap $352.29B), while YieldMax MSTR Option Income Strategy ETF trades at $15.74 (market cap $1.11B). The key difference: Merck & Co., Inc. is far larger — about 317.4× YieldMax MSTR Option Income Strategy ETF's market cap, and Merck & Co., Inc. pays a 2.38% dividend while YieldMax MSTR Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| MRK | MSTY | |
|---|---|---|
Market Cap | $352.29B | $1.11B |
Volume | 6,348,796 | 3,805,384 |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $67.85 |
52-Week Low | $82.49 | $11.55 |
Typical Hold Time | 98 Days | 30 Days |
Enterprise Value | $399.05B | — |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
MSTY, the YieldMax MSTR Option Income Strategy ETF, trades at $15.83, down 5.61% with a bearish technical signal. The fund generates weekly distributions through options strategies on MicroStrategy stock, with recent payouts ranging from $0.16 to $0.34. Despite high distribution rates exceeding 100% annualized, the fund has experienced significant NAV erosion, declining approximately 34% over six months according to 24/7 Wall Street analysis from July 2026.
The outlook remains challenging as MSTY's strategy sacrifices capital appreciation for income generation. While the high distribution rate provides income, the structural erosion of NAV presents substantial risk. Investors face the dual challenge of receiving taxable distributions while experiencing principal decline, making this suitable only for those prioritizing current income over capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
